{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:36:20Z","timestamp":1787884580033,"version":"build-2784847793"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Amiodarone is associated with significant long\u2010lasting adverse drug reactions (<jats:styled-content style=\"fixed-case\">ADR<\/jats:styled-content>s). Guidelines recommend laboratory monitoring during long\u2010term use. However, data of compliance with laboratory monitoring are lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of this study was to assess laboratory monitoring of liver and thyroid function during amiodarone prescribing from 1989 to 2011 in the Tayside, <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>, population (approximately 400\u00a0000) in relation to National Guidelines recommending laboratory monitoring every 6\u00a0months. We also report the population\u2010level incidence of abnormal liver and thyroid function in relation to total exposure of amiodarone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Utilizing well\u2010established record\u2010linkage database, a longitudinal retrospective analysis of 1413 patients on long\u2010term amiodarone was carried out, analyzing prescribing, biochemical, and clinical data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010six percent (46%), 28%, and 21% of patients underwent liver, thyroid, and combined testing, respectively, in accordance with guideline recommendations. Thirteen percent and 17% of patients did not have any <jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">TSH<\/jats:styled-content> testing, respectively. During follow\u2010up, 117 (9.5%) patients had an <jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content> 3\u00d7<jats:styled-content style=\"fixed-case\">ULN<\/jats:styled-content> and 16% patients had an abnormal <jats:styled-content style=\"fixed-case\">TSH<\/jats:styled-content>, (n=125, &lt;0.4\u00a0mU\/L and n=28, &gt;10\u00a0mU\/L). One hundred and forty patients (10%) required thyroxine replacement therapy, and 40 (3%) required on hyperthyroid medication. Total amiodarone exposure increased the likelihood of abnormal biochemical testing 2.5\u2010fold after 4\u00a0years therapy for liver and thyroid function (<jats:italic>P&lt;.0005)<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this population\u2010based study, adherence to laboratory monitoring guidelines was suboptimal. There was a positive correlation with total amiodarone exposure and biochemical abnormalities and development of thyroid disease compared to the general population, highlighting the need for improvement and continued amiodarone monitoring.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1755-5922.12258","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T06:53:18Z","timestamp":1489042398000},"source":"Crossref","is-referenced-by-count":16,"title":["Population\u2010level incidence and monitoring of adverse drug reactions with long\u2010term amiodarone therapy"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3076-7280","authenticated-orcid":false,"given":"Stephen","family":"Rankin","sequence":"first","affiliation":[{"name":"College of Medical, Veterinary Life Sciences University of Glasgow  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas H.","family":"Elder","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular and Diabetes Medicine, Ninewells Hospital and Medical School University of Dundee  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Ogston","sequence":"additional","affiliation":[{"name":"Department of Public Health University of Dundee  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular and Diabetes Medicine, Ninewells Hospital and Medical School University of Dundee  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chim C.","family":"Lang","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular and Diabetes Medicine, Ninewells Hospital and Medical School University of Dundee  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Choy","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular and Diabetes Medicine, Ninewells Hospital and Medical School University of Dundee  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005049.pub2"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00220-9"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.08.039"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.863"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euq350"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000041"},{"key":"e_1_2_8_8_1","unstructured":"SIGN.Cardiac Arrhythmias in Coronary Heart Disease. SIGN94 (Scottish Intercollegiate Guidelines Network).2007."},{"key":"e_1_2_8_9_1","volume-title":"British National Formulary (online)","author":"Committee JF","year":"2015"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.01.063"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.04.022"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1210\/jcem.86.1.7119","article-title":"Amiodarone\u2010induced thyrotoxicosis","volume":"86","author":"Daniels GH","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032089"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00341.x"},{"key":"e_1_2_8_15_1","first-page":"656","article-title":"Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs","volume":"12","author":"Raebel MA","year":"2006","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_8_16_1","first-page":"254","article-title":"Adherence to the NASPE guideline for amiodarone monitoring at a medical university","volume":"12","author":"Bickford CL","year":"2006","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2007.07.020"},{"key":"e_1_2_8_18_1","first-page":"489","article-title":"Development and pilot testing of guidelines to monitor high\u2010risk medications in the ambulatory setting","volume":"16","author":"Tjia J","year":"2010","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.09.010"},{"issue":"6","key":"e_1_2_8_20_1","first-page":"146S","article-title":"Rationale, development, and clinical outcomes of a multidisciplinary amiodarone clinic","volume":"18","author":"Sanoski CA","year":"1998","journal-title":"Pharmacotherapy"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.12.008"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5501"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(85)90238-8"},{"key":"e_1_2_8_24_1","first-page":"419","article-title":"Amiodarone hepatotoxicity in the context of the metabolic syndrome and right\u2010sided heart failure","volume":"18","author":"Mattar W","year":"2009","journal-title":"J Gastrointestin Liver Dis"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840090504"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2014.29.5.588"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.20.2395"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1755-5922.12258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1755-5922.12258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:23:53Z","timestamp":1696339433000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1755-5922.12258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/1755-5922.12258"],"URL":"https:\/\/doi.org\/10.1111\/1755-5922.12258","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,12]]},"article-number":"e12258"}}